Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 4, 2005. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a retirement fund.
Material Changes
The primary material change reported is a decrease in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan. As of February 3, 2005, the fund's holdings changed from 18,506,997 to 18,426,913 shares. This movement occurred at an average price of $44.81 per share.
Management Commentary and Risks
The filing notes that the Retirement Savings Plan is a discretionary fund for current and former employees. Two directors, Dr. J.P. Garnier and Dr. T. Yamada, are identified as potentially interested in the shares held in the fund in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding the company's operations are detailed in this text.
Key Facts for Investor Verification
- The reduction in ADR holdings by the US Retirement Savings Plan was 79,084 shares.
- The average transaction price for the movement was $44.81.
- Directors Dr. J.P. Garnier and Dr. T. Yamada have potential interests in the fund's holdings.
- This filing contains no operational financial results or forward-looking guidance.